ArticleFrontiers in medicine2026
Ectropion uveae in a pediatric patient with refractory NF1-associated glaucoma: a 4-year case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glaucoma secondary to neurofibromatosis type 1 (NF1) is a vision-threatening complication characterized by variable phenotypic expression. The prognostic significance of specific anterior segment signs, particularly ectropion uveae (EU), remains unclear. Case presentation: We report a 7-year-old girl with NF1 who presented with unilateral refractory glaucoma and prominent EU in the affected eye. Despite maximal medical therapy and sequential surgical interventions, including microcatheter-assisted transluminal trabeculotomy, subsequent scar tissue excision with goniotomy, and two sessions of transscleral cyclophotocoagulation, intraocular pressure (IOP) remained uncontrolled. Implantation of a glaucoma drainage device (GDD) resulted in initial IOP reduction, with IOP maintained at 16/18 mmHg during the first 3 months. At 1 year post-GDD, IOP was 23 mmHg, and brinzolamide was subsequently added. Conclusion: This 4-year longitudinal case highlights an association between prominent ectropion uveae and a refractory surgical course in this patient. Traditional angle surgeries appeared to carry a high risk of failure, whereas GDD implantation provided IOP reduction from 42 to 23 mmHg at 1 year, although adjunctive medication was subsequently required. This observation raises the question of whether earlier GDD implantation might prove beneficial in similar patients. However, this hypothesis requires validation in a larger series.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.